Our top pick for
ICL Group Ltd is an agricultural inputs business based in the US. ICL Group shares (ICL) are listed on the NYSE and all prices are listed in US Dollars. ICL Group employs 11,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$8.19|
|52-week range||$3.39 - $8.34|
|50-day moving average||$7.43|
|200-day moving average||$7.01|
|Wall St. target price||$7.34|
|Dividend yield||$0.155 (1.89%)|
|Earnings per share (TTM)||$0.31|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-0.49%|
|1 month (2021-09-22)||14.71%|
|3 months (2021-07-22)||22.60%|
|6 months (2021-04-22)||28.37%|
|1 year (2020-10-22)||120.16%|
|2 years (2019-10-22)||78.04%|
|3 years (2018-10-22)||33.61%|
|5 years (2016-10-21)||120.16%|
Valuing ICL Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ICL Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ICL Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, ICL Group shares trade at around 27x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
ICL Group's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 9.44. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ICL Group's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ICL Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.2 billion.
The EBITDA is a measure of a ICL Group's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$5.6 billion|
|Operating margin TTM||14.11%|
|Gross profit TTM||$1.5 billion|
|Return on assets TTM||5.16%|
|Return on equity TTM||10.22%|
|Market capitalisation||$10.6 billion|
TTM: trailing 12 months
There are currently 526,479 ICL Group shares held short by investors – that's known as ICL Group's "short interest". This figure is 90.8% up from 275,984 last month.
There are a few different ways that this level of interest in shorting ICL Group shares can be evaluated.
ICL Group's "short interest ratio" (SIR) is the quantity of ICL Group shares currently shorted divided by the average quantity of ICL Group shares traded daily (recently around 236089.23766816). ICL Group's SIR currently stands at 2.23. In other words for every 100,000 ICL Group shares traded daily on the market, roughly 2230 shares are currently held short.
However ICL Group's short interest can also be evaluated against the total number of ICL Group shares, or, against the total number of tradable ICL Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ICL Group's short interest could be expressed as 0% of the outstanding shares (for every 100,000 ICL Group shares in existence, roughly 0 shares are currently held short) or 0.0008% of the tradable shares (for every 100,000 tradable ICL Group shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ICL Group.
Find out more about how you can short ICL Group stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like ICL Group.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 36.81
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and ICL Group's overall score of 36.81 (as at 12/31/2018) is pretty weak – landing it in it in the 71st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like ICL Group is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 17.16/100
ICL Group's environmental score of 17.16 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ICL Group is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 10.83/100
ICL Group's social score of 10.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ICL Group is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 11.82/100
ICL Group's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that ICL Group is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. ICL Group scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that ICL Group has, for the most part, managed to keep its nose clean.
|Total ESG score||36.81|
|Total ESG percentile||71.32|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||2|
Dividend payout ratio: 86.19% of net profits
Recently ICL Group has paid out, on average, around 86.19% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.88% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ICL Group shareholders could enjoy a 1.88% return on their shares, in the form of dividend payments. In ICL Group's case, that would currently equate to about $0.155 per share.
ICL Group's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
ICL Group's most recent dividend payout was on 31 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 16 August 2021 (the "ex-dividend date").
Over the last 12 months, ICL Group's shares have ranged in value from as little as $3.39 up to $8.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ICL Group's is 0.4301. This would suggest that ICL Group's shares are less volatile than average (for this exchange).
ICL Group Ltd, together with its subsidiaries, operates as a specialty minerals and chemicals company worldwide. It operates in four segments: Industrial Products, Potash, Phosphate Solutions, and Innovative Ag Solutions (IAS). The Industrial Products segment produces bromine out of a solution that is a by-product of the potash production process, as well as bromine-based compounds; produces various grades of potash, salt, magnesium chloride, and magnesia products; and produces and markets phosphorous-based flame retardants and other phosphorus-based products. The Potash segment extracts potash from the Dead Sea; mines and produces potash and salt; produces Polysulphate; produces, markets, and sells magnesium and magnesium alloys, as well as related by-products, including chlorine and sylvinite; and sells salt. The Phosphate Solutions segment uses phosphate commodity products to produce specialty products; produces and markets phosphate-based fertilizers, as well as sulphuric acid, green phosphoric acid, and phosphate fertilizers; and manufactures thermal phosphoric acid for various industrial end markets, such as oral care, cleaning products, paints and coatings, water treatment, asphalt modification, construction, and metal treatment. It also develops and produces functional food ingredients and phosphate additives for use in the processed meat, poultry, seafood, dairy, beverage, and baked goods markets; and produces milk and whey proteins for the food ingredients industry. The IAS segment develops, manufactures, markets, and sells fertilizers based primarily on nitrogen, potash, and phosphate, including water soluble specialty, liquid, soluble, and controlled-release fertilizers.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.